A living WHO guideline on drugs for COVID-19

Published by Francois Lamontagne on Sep 8, 2020

Disclaimer

Sponsors

This guideline has been developed in collaboration between the World Health Organisation (WHO) and the MAGIC Evidence Ecosystem Foundation. It has been published as WHO guidance. No specific funding has been provided beyond in-kind resources by the organisations involved, including the BMJ.

Contact

Abstract

Language

en

PICOS

PICO 1.1

Population
Patients with critical COVID-19 infection
Intervention
Steroids
Comparator
Standard Care
Outcomes

PICO 1.2

Population
Patients with severe COVID-19 infection
Intervention
Steroids
Comparator
Standard Care
Outcomes

PICO 1.3

Population
Patients with non-severe COVID-19 infection
Intervention
Steroids
Comparator
Standard Care
Outcomes